“NORML PAC believes strongly that Senator Ebbin has the tenacity, coalition building skills, and political acumen required to help end our country’s destructive war on marijuana consumers,” stated NORML PAC Manager Erik Altieri, “Outgoing Congressman Jim Moran has a long history of supporting important marijuana law reform proposals at the federal level and Adam Ebbin is a proven and effective leader that will carry on that important legacy by working to roll back the damage marijuana prohibition is having on families and communities across the nation.”
“I have a record of supporting decriminalization and, like President Obama, do not believe that the effects of marijuana are more harmful than alcohol,” Senator Ebbin said. “For more than a decade, I’ve been fighting for progressive causes in the General Assembly. In Virginia, marijuana-related arrests make up over 50% of all drug-related arrests, costing the state over $67 million. We must focus our time and resources on job creation, clean energy, healthcare, education, and our economy. I look forward to continuing my work for our shared progressive values as the next member of Congress from the 8th District.”
State affiliate Virginia NORML is also joining NORML PAC in their support of Senator Ebbin’s campaign.
“Virginia NORML realizes that any federal cannabis policy reform will act as a powerful catalyst for changing our state laws,” commented Virginia NORML Communications Director Duane Ludwig, “We are excited to endorse Adam Ebbin for Congress because he will be a bold, progressive advocate for fair and reasonable cannabis policy.”
In Virginia, more than 4 out of 5 residents support the legalization of medical marijuana and a majority support decriminalization. A recent poll revealed that in Northern Virginia, where the 8th Congressional District is located, over 50% of residents support fully legalizing and regulating marijuana.
The Democratic Primary for the Virginia 8th District is on June 10th. You can check your voter information and find your polling place here.
You can click here to join NORML PAC in supporting Senator Ebbin’s campaign and learn more about his platform. Below is a video from a recent NAACP candidate forum in which Senator Ebbin calls for decriminalization and legalization in addition to casting a spotlight on Arlington’s egregious racially disparate marijuana arrests.
In an interview with NPR released today, retired Supreme Court Justice John Paul Stevens came out in support for marijuana legalization.
When asked if he believed the federal government should legalize marijuana, the 94 year old former Justice replied:
“Yes, I really think that that’s another instance of public opinion [that's] changed. And recognize that the distinction between marijuana and alcoholic beverages is really not much of a distinction. Alcohol, the prohibition against selling and dispensing alcoholic beverages has I think been generally, there’s a general consensus that it was not worth the cost. And I think really in time that will be the general consensus with respect to this particular drug.”
You can listen to the full interview from National Public Radio here.
Stevens joins the majority of Americans who are ready to see an end to our war on marijuana consumers and for the country to move towards a system of legalization and regulation.
Dear NORML members and supporters,
As always, there will be large public gatherings all around America (and other countries too) to celebrate the responsible adult use of cannabis. The day is a cultural phenomenon, with both substantial media output (some entire cable networks broadcast cannabis-centric programming and entertainment–like Comedy Central) and coverage of public celebrations (cities like Denver expect downtown public pot celebrations drawing 80,000 or more Saturday and Sunday).
The patchwork of cannabis law enforcement in this country is so disparate that in some locations the gatherings will celebrate their appreciation of the herb, but under harsh threat of arrest and criminal sanctions. Contrastingly, in other parts of the country, where I write this letter from, the city of Denver–where I’ve paid an effective 35% tax rate on the retail purchase of a small amount of a strain called ‘Tangie’, and where over 40,000 attendees are expected for High Times’ Cannabis Cup Awards–the events here are decidedly in celebration of the only place currently on earth where an adult can purchase and legally consume cannabis in a similar manner to that of alcohol products.
By July of this year, the citizens and visitors to Washington State will enjoy the same freedoms and responsibilities when their cannabis retail market officially commences.
Two down, forty-eight more states and territories to go…
For over a dozen years NORML has had unique 4/20 fundraisers, promoting an annual membership* for as low as $4.20, and this year is no different. Hats off to legalization–upgrade your membership for $42 and get a limited edition hemp hat* from Grassroots California.
With Alaska and Oregon voters likely propelling their states to join Colorado and Washington this election season via binding voter initiatives, we will all have even more to rejoice (and consumer choices for safe, affordable, legal and taxed cannabis) next April 20th.
Thank you for supporting NORML’s long standing public advocacy efforts to end cannabis prohibition and replace it with a far more rational and responsible public policy that has sustained the organization to this day–when I’m reporting to you the first legal and taxed cannabis purchase in my lifetime.
Allen St. Pierre
* NORML 420 membership offer is valid until 4/20/14 at 11:59pm EST. (Limited quantity of hemp hats)
Tampa, FL – On Sunday April 13th, people came from all parts of the sunshine state to the to attend the first statewide Florida NORML conference at the University of South Florida. While the most critical topic of the day was Question 2 (Florida’s medical marijuana ballot initiative) to be voted on in the November election, there was also a diverse range of information presented by conference speakers such as student rights on campus, organizing and social media outreach.
Panelists consisted of a group of nationally recognized advocates and some of the state’s most high profile reformers. They included federal medical marijuana patient Irv Rosenfeld, Kathy Jordan of the Kathy Jordan Medical Marijuana Act, the Silver Tour’s Robert Platshorn and Florida NORML Chapter Director Karen Goldstein. Other speakers included Catherine Sevcenko, litigation coordinator for the Foundation for Individual Rights in Education (FIRE) and Eli Zucker, Founding Director of USF NORML and Sabrina Fendrick of National NORML.
The event was organized and hosted by the USF NORML chapter, with support from Students for Liberty and United for Care – the campaign behind Question 2. For more information in how to get involved with marijuana law reform in the sunshine state, please contact Karen Goldstein at firstname.lastname@example.org.
Lawmakers in Alabama and Utah recently approved legislation seeking to authorize the physician-supervised use of varieties of cannabis and/or extracts high in the non-psychotropic cannabinoid cannabidiol (CBD). Both measures, which I previously summarized as ‘largely unworkable,‘ have now been signed into law.
In recent days, lawmakers in three additional states — Kentucky, Mississippi, and Wisconsin — have similarly signed off on CBD-explicit legislation. These measures are now awaiting signatures from each states’ respective Governors.
Similar to Alabama’s SB 174 (aka ‘Carley’s Law), which only permits the use of CBD by prescription during the course of an FDA-approved clinical trial, the pending Kentucky and Wisconsin bills may also be classified as ‘research-centric’ measures. Kentucky’s SB 124 permits physicians “practicing at a hospital or associated clinic affiliated with a Kentucky public university” to “dispense” cannabidiol during the course of an FDA-approved clinical trial. Wisconsin’s AB 726 similarly limits those who may legally dispense CBD to only include those physicians who have obtained an FDA-issued investigational drug permit to prescribe it. In Tennessee, lawmakers are also close to finalizing similar language (included in HB 2461 and SB 2531) that seeks to allow university clinical researchers to “manufacture” and “dispense” high-CBD cannabis oil “as part of a clinical research study on the treatment of intractable seizures.” (By contrast, separate, broader medical cannabis measures seeking to authorize the use of the whole plant failed this year in all three states.)
As I’ve previously written here and here, it is unlikely that specific changes in state law will stimulate these type of proposed clinical trials from taking place in these states any time soon. Because CBD is acknowledged by federal regulators to be classified as a schedule I prohibited substance, multiple federal agencies — including the FDA, DEA, NIDA (US National Institute of Drug Abuse), and PHS (Public Health Service) must all sign off on any clinical investigation of the cannabinoid — a process that typically takes several years. A keyword search of FDA-approved clinical trials using the terms “cannabidiol” and “United States” yields fewer than ten ongoing human trials involving CBD — less than half of which are assessing its potential therapeutic application. (Two additional safety trials assessing the use of GW Pharmaceutical’s patented high-CBD formulation Epidiolex in children with severe epilepsy are also ongoing.)
Unlike the above-mentioned measures, Mississippi’s HB 1231, does not seek to encourage state-sponsored clinical trials. Rather, the measure exempts specific high-CBD formulated oils “that contain more than fifteen percent cannabidiol [and] … no more than one-half of one percent of tetrahydrocannabinol” from the state’s definition of a schedule I prohibited substance. However, like Utah’s HB 105 (aka ‘Charlee’s Law), Mississippi’s pending law does not provide guidance as to where patients could legally obtain such extracts. Though such high-CBD products are presently available in a limited number of medical cannabis states (such as in California and Colorado), these extracts are typically only available to in-state residents who possess authorization from a physician licensed to practice in that state. (Although Colorado state law also allows for a recreational cannabis market, which may be legally accessed by out-of-state residents, at present time such high-CBD concentrates are seldom available at retail outlets.)
Additional cannabidiol-specific measures also remain pending in Florida and South Carolina, among other states. NORML will report on these measures as they progress and we will continue to express caution in regards to their practical utility for those patients who require immediate access to whole-plant cannabis and its variety of naturally-occurring compounds.